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bjectives We sought to examine the short- and long-term outcomes of blood transfusion in pa-
ients presenting with ST-segment elevation myocardial infarction (STEMI).
ackground The short- and long-term consequences of blood transfusion in anemic patients with
ecent STEMI remain controversial.
ethods We evaluated 30-day, 6-month, and 1-year all-cause mortality among 4,131 STEMI patients
nrolled in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIb trial. Pa-
ients were categorized according to whether they received a blood transfusion during hospitaliza-
ion. Cox proportional hazards survival models with transfusion as a time-dependent covariate were
onducted for the whole and for the propensity-matched groups. Additionally, a series of sensitivity
nalyses assessed the magnitude of hidden bias that would need to be present to explain the asso-
iations actually observed.
esults Death at 30 days (13.7% vs. 5.5%), 6 months (19.7% vs. 6.9%), and 1 year (21.8% vs. 8.7%)
as signiﬁcantly higher for transfused patients than for nontransfused patients, respectively. After
djusting for over 25 baseline characteristics, nadir hemoglobin, and propensity score for transfu-
ion, and using transfusion as a time-dependent covariate, transfusion remained signiﬁcantly associ-
ted with increased risk of mortality at 30 days (hazard ratio [HR]: 3.89, 95% conﬁdence interval [CI]:
.66 to 5.68, p  0.001), 6 months (HR: 3.63, 95% CI: 2.67 to 4.95, p  0.001), and 1 year (HR: 3.03,
5% CI: 2.25 to 4.08, p  0.001). Similar results were observed in the propensity-matched patients.
onclusions Blood transfusion is associated with increased short- and long-term mortality in the
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47p to one-fifth of the patients with acute coronary syn-
romes (ACS) may have anemia at presentation (1–5). Even
hough the cardiovascular adverse consequences of anemia
n the setting of ACS have been well reported in the
iterature (1–3,5,6), opinion about blood transfusion to
orrect anemia is divided (7–11). Some studies have sug-
ested potential harm where others have suggested benefit
7–10). The decision to transfuse becomes important in
atients with ST-segment elevation myocardial infarction
STEMI) given the high mortality and the need for urgent
See page 54
hrombolysis or angioplasty that may further increase the
isk of bleeding (12,13). Additionally, the abrupt and
omplete coronary occlusion seen in STEMI may make the
dverse consequences of anemia more pronounced (14). On
he other hand, STEMI is associated with increased viscos-
ty and thrombogenicity that may be worsened by transfu-
ion of stored blood (15–18), leading to further decrease in
icrocirculatory flow and poor oxygen delivery (19). There-
ore, we sought to examine the impact of blood transfusion
n short- and long-term all-cause mortality in the setting of
TEMI.
ethods
he GUSTO IIb trial. The GUSTO (Global Use of Strategies to
pen Occluded Coronary Arteries) IIb trial has been described
n detail elsewhere (20). Briefly, GUSTO IIb was a multicenter
rial conducted in 373 hospitals in 13 countries between May
994 and October 1995 to compare the clinical efficacy of the
irect thrombin inhibitor, recombinant hirudin, with that of
eparin (an indirect antithrombin agent) in patients with
nstable angina or acute myocardial infarction. Acute coronary
yndrome patients were stratified according to the presence of
TEMI on the baseline electrocardiogram (4,131 patients) or
ts absence (unstable angina or non–Q-wave myocardial infarc-
ion). The primary composite end point for the trial was death
r nonfatal myocardial infarction in the first 30 days of
ollow-up.
tudy population. Our study population was restricted to
atients enrolled in the GUSTO IIb trial who had transient
r persistent ST-segment elevation of more than 0.5 mm on
he baseline electrocardiogram. From a total of 4,131
atients with STEMI enrolled in the GUSTO IIb trial, we
urther excluded 53 patients who did not have information
bout blood transfusion and 503 patients who were part of
substudy of direct coronary angioplasty, leaving 3,575
atients in our study cohort.
lood transfusion and outcomes. The information about
ransfusion was prospectively collected in the trial. Patient’s
emoglobin and hematocrit values on admission (the first
easurement within 24 h of admission) were recorded as fhe baseline value. The lowest hemoglobin during the
ospital stay was recorded as the nadir hemoglobin. Patients
ere divided into 2 groups, those who received transfusion
any transfusion of whole blood or packed red blood cells) at
ny point during the hospital stay, and those who did not.
leeding was categorized in accordance with the GUSTO
Ib trial into severe or life-threatening (either intracranial
emorrhage or bleeding that causes hemodynamic compro-
ise and requires intervention), moderate bleeding (no
vidence of hemodynamic compromise but requiring blood
ransfusion), and mild bleeding (all others). The principal
utcome was all-cause mortality at 30 days, 6 months, and
year.
tatistical analysis. Baseline clinical, hematological, and de-
ographic characteristics of those who received transfusion
nd those who did not were compared by the chi-square test
r Fisher exact test for categorical variables and by the t test
r Kruskal-Wallis test for continuous variables. Rates of
reedom from events at 30 days, 6 months, and 1 year were
alculated via the Kaplan-Meier approach.
To determine the independent effect of transfusion on
ortality, we used Cox proportional hazards survival mod-
ls that adjusted for over 25 baseline characteristics includ-
ng age; gender; race; height;
eight; country of origin; co-
orbidities including diabetes,
ypertension, hypercholesterol-
mia; smoking; chronic obstruc-
ive pulmonary disease; chronic
enal insufficiency; peripheral
rterial disease; heart failure;
troke; cancer diagnosed in the past 5 years; and history of
oronary artery bypass grafting and percutaneous coronary
rtery interventions. Adjustments were also made for Killip
lass at presentation, family history of cardiac diseases and
isk factors, and medical therapy and interventions (both
mbulatory and in-hospital). Transfusion was adjusted for
s a time-dependent covariate to account for the effect of
iming of transfusion and to eliminate the potential bias of
ot receiving a blood transfusion because of death (sur-
ival bias).
Because transfusion was not randomly assigned in the
USTO IIb trial, multivariable analysis alone may not
dequately control for confounding and bias. Hence, we
urther analyzed the data using propensity score and match-
ng (21). A propensity score for transfusion was generated
or 30 days, 6 months, and 1 year separately using logistic
egression analysis that included all variables shown in
able 1. To be more conservative and to try to underes-
imate the hazard of transfusion, the propensity analysis
as conducted for those that received blood transfusion
r for those that had moderate or severe bleeding (n 
16). Subsequently, each patient who had a blood trans-
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
STEMI  ST-segment
elevation myocardial
infarctionusion or had moderate to severe bleeding without
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48ransfusion was matched with 2 patients without trans-
usion using the propensity score. Nadir hemoglobin was
ot included in building the propensity score but was
djusted for in the final model. To confirm the validity of
ur propensity analysis, a time-dependent Cox regression
nalysis stratified by quintiles of propensity score was
onducted.
Even though propensity score and matching were ad-
Table 1. Baseline Characteristics
Characteristic
Rece
Age, yrs
Female gender, n (%)
Black race, n (%)
Height, cm, mean SD
Weight, kg, mean  SD
Medical history, n (%)
Cancer diagnosed in last 5 yrs
History of congestive heart failure
Peripheral vascular disease
History of cigarette smoking
History of cerebrovascular disease
Family history of coronary heart disease
History of angina
History of coronary bypass surgery
History of percutaneous coronary intervention
Clinical presentation
Heart rate, beats/min, mean  SD
Systolic blood pressure, mm Hg, mean  SD
Diastolic blood pressure, mm Hg, mean  SD
Baseline Killip class, n (%)
I
II
III
IV
Coexisting conditions, n (%)
Renal insufﬁciency
Diabetes
Hypercholesterolemia
Hypertension
Severe chronic obstructive lung disease
Procedures performed within 168 h after randomization, n (%)
Percutaneous coronary intervention
Coronary artery bypass graft surgery
Hematological parameters
Baseline hemoglobin, g/dl, median  IQR
Baseline hematocrit, g/dl, median  IQR
Nadir hemoglobin, g/dl, median  IQR
Nadir hematocrit, g/dl, median  IQR
Moderate or severe bleeding, n (%)
Other variables not shown in the table but included in the analysis were height, weight, country of s
IQR interquartile range; SD standard deviation.usted to control for overt biases, hidden bias is more Nifficult to address because potential confounding variables
ay not have been measured. Therefore, sensitivity
nalysis was performed to examine the magnitude of the
idden bias that would have to be present to explain the
ssociations observed (22). Proportional hazard assump-
ion was tested for all time points by examining the
nteraction between blood transfusion and time. All analyses
ere performed using SAS version 9.2 (SAS Institute, Cary,
ransfusion
307)
Did Not Receive Transfusion
(n  3,268) p Value
 11 62 12 0.001
(41) 726 (22) 0.001
(6) 79 (2) 0.001
 10 171 9 0.001
 14 79 15 0.001
(5) 101 (3) 0.16
(4) 91 (3) 0.26
(10) 234 (7) 0.06
(64) 2,297 (70) 0.01
(0.3) 18 (0.5) 1.00
(42) 1,215 (38) 0.17
(60) 1,569 (48) 0.001
(7) 165 (5) 0.11
(6) 183 (6) 0.51
 19 76 17 0.10
 19 130 23 0.55
 15 78 14 0.06
0.001
(83) 2,868 (88)
(16) 331 (10)
(0.9) 38 (1.1)
(0.3) 16 (0.5)
(2) 14 (0.43) 0.01
(19) 507 (15) 0.09
(37) 1,180 (36) 0.71
(45) 1,303 (40) 0.07
(4) 82 (2) 0.10
(18) 67 (21) 0.11
(2) 86 (27) 0.001
 2.0 14.7 4.1 0.001
 5.6 43.2 4.2 0.001
 1.4 12.6 3.8 0.001
 4.3 37.2 5.1 0.001
(97) 19 (0.6) 0.001
story ofmyocardial infarction, previous angina, prior exposure to hirudin, and priormedication use.ived T
(n 
67
126
17
167
73
14
12
31
195
1
126
185
22
20
78
130
77
251
49
3
1
6
59
115
139
12
596
68
13.9
41.4
8.6
25.1
297
tudy, hiorth Carolina).
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49esults
aseline characteristics. From a total of 3,575 STEMI
atients, 1,605 (44.9%) patients were from the U.S. and
anada, 1,749 (49.0%) from Europe, and 221 (6.1%) from
ustralia and New Zealand. Of 3,575 study patients, 307
8.6%) received a transfusion during their hospitalization. In
eneral, patients who underwent blood transfusion were
lder, more likely to be female, had Killip class 2 on
resentation and were more likely to have a prior history of
hronic renal insufficiency, angina, and smoking (Table 1).
ut of 307 patients in the transfusion group, 297 (96.7%)
atients had moderate to severe bleeding. Patients in the
ransfusion group had lower nadir hemoglobin and required
n average of 3.5  2.9 U of blood transfusion per patient.
nadjusted analysis. Patients receiving transfusions had a
ignificantly higher rates of mortality when compared with
ontranfusion patients at 30 days (13.7% vs. 5.5%, p 
.01), 6 months (19.7% vs. 6.9%, p  0.01), and 1 year
21.8% vs. 8.7%, p  0.01). Kaplan-Meier curves for death
t 30 days (Fig. 1A), 6 months (Fig. 1B), and 1 year (Fig.
C) show a nonproportional increase in mortality with
lood transfusion. Similarly, unadjusted Cox proportional
azards survival models with transfusion as a time-
ependent covariate showed a strong association between
lood transfusion and all-cause mortality (Table 2).
ultivariable and propensity score adjusted analysis. Trans-
usion was strongly associated with all-cause mortality in
ultivariable Cox proportional-hazard analysis for 30 days,
months, and 1 year with transfusion as a time-dependent
ovariate (Table 2). Additionally, transfusion was associated
ith increased 30-day, 6-month, and 1-year mortality when
ll patients were included in the model that adjusted for
ropensity to receive transfusion. Transfusion was also
ssociated with incident myocardial infarction at 30-day
chi-square: 32.53, adjusted hazard ratio [HR]: 3.44, p 
.001) and 6-month (chi-square: 26.30, adjusted HR: 2.69,
 0.001).
ropensity-matched analysis. To account for the differences
n baseline characteristics between the 2 groups, propensity
nalyses for 30 days, 6 months, and 1 year were performed
eparately. In these analyses, each patient that had blood
ransfusion or had moderate to severe bleeding was matched
ith 2 individuals in the no blood transfusion group using a
ropensity score. Of the 316 subjects that underwent blood
ransfusion or had moderate to severe bleeding, all 316
100%) were matched with 2 patients that did not receive
ransfusion, indicating an excellent number of matched
atients with good statistical discrimination (C statistic:
.81, 0.84, and 0.82 for the 30 days, 6 months, and 1 year
odels, respectively).
Despite the propensity-matched analysis, transfusion re-
ained an independent and strong predictor of all-cause
ortality at 30 days (Fig. 2A), 6 months (Fig. 2B), and 1 mear (Fig. 2C) in unadjusted models. Similarly, in Cox
roportional hazards survival models that used transfusion
s a time-dependent covariate and adjusted for over 25
ariables in addition to propensity score, transfusion was
ssociated with a higher risk of 30-day, 6-month, and 1-year
ortality (Table 2). Proportional hazard assumption was
Figure 1. Kaplan-Meier Curves for Mortality in the Overall Population
Kaplan-Meier curves (A) for 30-day mortality in the overall population (n 
3,575), (B) for 6-month mortality in the overall population (n  3,538), and
(C) for 1-year mortality in the overall population (n  3,465).et because the interaction between transfusion as a time-
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50ependent variable and time was not significant in any of
he models.
alidity and sensitivity analysis. Among all quintiles of
ropensity score, baseline characteristics were well matched
nd transfusion remained significantly associated with all-
ause mortality for each quintile confirming the validity of
ur propensity analysis (22). A simple sensitivity analysis
hat introduced a single sensitivity parameter gamma that
easured the degree of departure from random assignment
f treatment, which in our case was transfusion, was
erformed (22). In all 3 matched models (30 days, 6
onths, and 1 year), we tested gamma from 1 to 6. For all
odels, at gamma  6, the p value was  0.01, indicating
ur results are highly insensitive to bias and that hidden bias
as to be enormous to alter our conclusions (22).
iscussion
e observed a higher death rate at 30 days, 6 months, and
year in patients with STEMI receiving blood transfusions.
atients in the blood transfusion group had lower hemo-
lobin levels, were older, and had a higher prevalence of
ardiovascular risk factors, but the increased mortality in the
ransfusion group persisted even after adjustment for base-
ine characteristics, nadir hemoglobin, comorbidities, in-
ospital medical therapy, and procedures. Additionally, the
Table 2. Univariate and Multivariable Cox Proportional Hazards Survival Mo
According to 30-Day, 6-Month, and 1-Year Mortality for the Whole Populat
Variables Number of Death
All patients
30-day (n  3,575) 221 (6)
Unadjusted —
Multivariable adjusted —
6-month (n  3,575)* 285 (8)
Unadjusted —
Multivariable adjusted —
1-year (n  3,575)† 340 (10)
Unadjusted —
Multivariable adjusted —
Propensity-matched patients
30-day (n  948) 96 (10)
Unadjusted —
Multivariable adjusted —
6-month (n  958) 128 (13)
Unadjusted —
Multivariable adjusted —
1-year (n  958) 152 (16)
Unadjusted —
Multivariable adjusted —
*A total of 37 patients were lost to follow-up at 6 months. †A total of 110 patients were lost to follo
— not applicable.ssociation persisted across all statistical models and was even stronger when patients were matched based on pro-
ensity to receive transfusion.
The historic clinical standard of transfusing when the
emoglobin levels dropped below 10 g/dl was challenged in
arlier studies in patients admitted to the intensive care
nits or undergoing coronary artery bypass graft surgery
21,23). These studies established that routine transfusion
an lead to increased mortality, prolonged hospital length of
tay, and adverse outcomes (21,23). Although, the associa-
ion between anemia and clinical outcomes is well estab-
ished in patients presenting with ACS, the literature on the
ole of transfusion is more limited and has yielded conflict-
ng results (9,10,24). Few studies have shown improved
utcomes with blood transfusion (9), and others have
uggested harm (7,8,10). Overall, few studies have exam-
ned the association between blood transfusion and long-
erm mortality. Additionally, potential biases and con-
ounding may have led to the contradictory results observed
n these studies (7–10,25).
In a retrospective analysis of non-STEMI patients en-
olled in 3 clinical trials, Rao et al. (8) showed that
ransfusion was associated with increased hazard for 30-day
ortality (adjusted HR: 3.94, 95% CI: 3.26 to 4.75).
owever, the investigators (8) did not conduct propensity-
atched analysis, and long-term effects of transfusion on
ortality could not be ascertained from the study. Sabatine
for Blood Transfusion
d the Propensity-Matched Patients
Hazard Ratio (95% Confidence Interval) p Value
— —
6.12 (4.31–8.69) 0.001
3.89 (2.66–5.68) 0.001
— —
5.63 (5.31–5.97) 0.001
3.63 (2.67–4.95) 0.001
— —
4.52 (4.27–4.77) 0.001
3.03 (2.25–4.08) 0.001
— —
3.84 (2.45–6.02) 0.001
5.44 (3.21–9.22) 0.001
— —
3.75 (2.57–5.48) 0.001
4.81 (3.00–7.71) 0.001
— —
3.13 (2.92–3.35) 0.001
3.10 (2.18–4.40) 0.001
t 1 year.dels
ion an
s (%)
w-up at al. (26) in a post hoc analysis of pooled ACS clinical trials
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51howed an interaction between STEMI and blood transfu-
ion, whereby transfusing STEMI patients with hemoglo-
in below 12 g/dl was associated with lower mortality but an
ncreased risk of adverse events and death among non-
TEMI patients who were transfused. In a retrospective
Figure 2. Kaplan-Meier Curves for 30-Day Mortality in
Propensity-Matched Population
Kaplan-Meier curves (A) for 30-day mortality in propensity-matched population
(n  943), (B) for 6-month mortality in propensity-matched population (n 
958), and (C) for 1-year mortality in propensity-matched population (n  958).tudy of Medicare data, Wu et al. (9) showed improved survival in elderly patients with STEMI if hematocrit was
elow 30%. However, the investigators (9) excluded all
atients younger than 65 years and those having bleeding
ithin 48 h of admission, which limits the generalizability
f the study. Additionally, their study was limited to 30-day
utcomes and did not consider propensity analysis. Our
tudy supports the findings of Rao et al. (8) and demon-
trates that transfusion is associated with both short- and
ong-term mortality in patients with STEMI.
The exact reasons for the harmful effect of blood trans-
usion in the setting of STEMI are not yet completely
nderstood. Animal models have shown that STEMI is a
tate of increased viscosity, and transfusion may lead to
ecreased microcirculatory flow and poor oxygen delivery
27–29). Some of the harm may also be due to blood being
tored for prolonged periods (30–32). In vitro studies show
hat stored red blood cells undergo various morphologic and
unctional changes from discoid to spherical that decreases
heir ability to deform and pass through microcirculation.
dditionally, there is depletion of 2,3-diphosphoglycerate,
hereby reducing red blood cells’ capacity to carry oxygen as
ell as increasing free radical production (19,33–37).
hether these changes account for the majority of in vivo
dverse outcomes associated with transfusion is uncertain at
his time (23,38,39). It has been suggested that, with
ncreased hemoglobin, the platelets are exposed to increased
hear forces, which increases platelet aggregation toward the
essel wall and may worsen ischemia (40,41).
Recently Bennett-Guerrero et al. (42) and Reynolds et al.
43) suggested that stored blood results in loss of nitric oxide
ioactivity, leading to decreased levels of S-nitrosothiol
emoglobin in stored blood. However, repletion of stored
lood with nitric oxide led to increased levels of
-nitrosothiol hemoglobin and improved vasodilatory re-
ponse to hypoxia (42,43).
Our study also showed long-term increase in mortality
ith blood transfusion. Because the life of a red blood cell
s around 120 days it is not clear why patients receiving
lood transfusion would have long-term adverse events.
ne potential explanation for this is the immunomodula-
ory and pro-inflammatory properties of transfused blood. A
umber of pro-inflammatory mediators are released from
hite blood cells during storage. These include myeloper-
xidase, plasminogen activator inhibitor-1, eosinophil pro-
ein X, and histamine (44). Collectively, these factors may
nhance atherosclerosis or lead to diffuse inflammation
ithin the coronary tree. Furthermore, in the setting of
TEMI, they may have adverse effects on the infarcted
yocardium.
tudy limitations. Our study has several limitations in that
ur results are based on a post hoc analysis of prospectively
ollected, randomized, controlled trial data. Hence, there is
possibility of unmeasured biases. However, a series of
tatistical modeling and adjustments including propensity
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52nalysis only strengthened the relationship between blood
ransfusion and mortality. Sensitivity analysis also showed
hat hidden bias had to be extraordinary to alter our results.
lso, GUSTO IIb included a broad representation of
opulation with a wide spectrum of coexisting conditions,
ut it may still not reflect the real world population. In
ddition, data regarding age of stored blood or ABO blood
roups compatibility were noted as available. Lastly, this
ohort is outdated and the current therapies (pharmacolog-
cal and interventional) have drastically changed during this
eriod. However, bleeding remains an important complica-
ion associated with pharmacologic therapy in patients
resenting with ACS and its treatment with stored blood
roduct has not changed since the GUSTO IIb era.
onclusions
n patients with STEMI, blood transfusion was an inde-
endent predictor of both short- and long-term mortality.
he relationship between transfusion and clinical outcomes
ersisted after adjustment for a wide array of baseline
haracteristics including nadir hemoglobin and in-hospital
reatments. Our study results warrant a prospective, ran-
omized clinical trial to determine whether blood transfu-
ion to target specific hemoglobin levels improves outcomes
n patients with STEMI. There certainly appears to be a
oundation for evaluating newer methods that may avoid the
otential adverse impact of stored blood.
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